Mendus announces request for conversion of convertible bonds by Negma Group
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group has by notice to Mendus requested the conversion of convertible bonds... | March 30, 2023
Mario Brkulj Erik Manting Corey Davis Lifesci Advisors Swedish Companies Registration Office Negma Group
Source: marketscreener.com